ripretinib Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumors WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 12, 2020– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced

Antibiotic resistance in an intensive care unit

A study coordinated by the UPV/EHU-University of the Basque Country did not detect any increase in antimicrobial susceptibility after applying a selective digestive decontamination (SDD) protocol. The research, conducted in collaboration with the Microbiology Service